Understanding how to control inflammation and improve lung function during sepsis
Control of septic inflammation and lung microvascular endothelial barrier by cell junction signaling nexus
['FUNDING_R01'] · UNIVERSITY OF MARYLAND BALTIMORE · NIH-10861795
This study is looking at how lung infections can cause serious problems in the body during sepsis and is exploring a protein called Rap1 that might help heal lung blood vessels after they get hurt, with the hope of finding new treatments to help patients recover better from sepsis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MARYLAND BALTIMORE (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10861795 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind sepsis, particularly how lung infections can lead to severe inflammation and damage to blood vessel barriers. The study focuses on a specific protein, Rap1, which may help restore the integrity of lung blood vessels after injury. By examining how Rap1 interacts with other proteins involved in cell junctions, the research aims to identify potential treatments that could enhance recovery from sepsis-related lung damage. Patients may benefit from new therapies that improve lung function and reduce complications from sepsis.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients experiencing sepsis, particularly those with lung infections.
Not a fit: Patients with sepsis not involving lung infections or those with advanced organ failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery outcomes for patients suffering from sepsis-related lung injuries.
How similar studies have performed: Previous research has shown promise in targeting cell junctions to improve vascular integrity, suggesting that this approach may yield beneficial results.
Where this research is happening
BALTIMORE, UNITED STATES
- UNIVERSITY OF MARYLAND BALTIMORE — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BIRUKOVA, ANNA — UNIVERSITY OF MARYLAND BALTIMORE
- Study coordinator: BIRUKOVA, ANNA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.